Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
- 18 February 2016
- journal article
- research article
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 20 (2) , 175-181
Abstract
Introduction The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results In univariate analysis, TNM stage (p < 0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p < 0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.Keywords
Funding Information
- National Clinical Key Discipline
- Priority of Shanghai key discipline of medicine (81071791)
- National Natural Science Foundation of China (81401963)
This publication has 42 references indexed in Scilit:
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated MalignanciesClinical Cancer Research, 2013
- Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancerJournal of Translational Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal CarcinomaClinical Cancer Research, 2012
- Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancerGut, 2010
- Colorectal cancerThe Lancet, 2010
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008